https://www.selleckchem.com/pr....oducts/bismuth-subni
To evaluate the pharmacology, pharmacokinetics, clinical efficacy, safety, dosing, cost, and clinical implications of enfortumab vedotin-ejfv (EV) in the treatment of locally advanced or metastatic urothelial carcinoma (UC). A literature search of PubMed (inception to August 202 was conducted using the terms , and . Data were also obtained from package inserts, meeting abstracts, and ongoing studies from ClinicalTrials.gov. All relevant published articles, package inserts, and meeting abstracts evaluating EV for the treatme